Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

July 31, 1998

Conditions

HIV InfectionsPregnancy

Interventions

BIOLOGICAL

rgp120/HIV-1MN

Trial Locations (6)

Univ. of Rochester ACTG CRS, Rochester

Washington U CRS, St Louis

St. Louis ConnectCare, Infectious Diseases Clinic, St Louis

Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore

San Francisco Gen. Hosp., San Francisco

UCSF Pediatric AIDS CRS, San Francisco

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH